Gynecologic oncology
-
Gynecologic oncology · Feb 2002
Effect of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells.
To determine whether combination treatment consisting of p53 gene transfer and cisplatin (CDDP) improves prognosis of ovarian cancer patients with peritonitis carcinomatosa, we tried this therapy in a peritonitis carcinomatosa model that we developed. ⋯ The present study suggests that intraperitoneal treatment with AxCAp53 and CDDP is potentially useful as an adjuvant therapeutic modality for peritonitis carcinomatosa, although further study is needed to improve the long-term survival for those patients.
-
Gynecologic oncology · Jan 2002
The clinical course of deep vein thrombosis in patients with gynecologic cancer.
The aim of this study was to evaluate the survival of gynecologic cancer patients diagnosed with deep vein thrombosis. ⋯ The development of DVT in conjunction with a gynecologic malignancy connotes a poor prognosis, especially in patients with cervical cancer. It is possible that this poor prognosis is related to the pathophysiology that results in venous thrombosis and not just the presence of cancer.
-
Gynecologic oncology · Nov 2001
Potential benefit of lymphadenectomy for the treatment of node-negative locally advanced uterine cancers.
The aim of this study was to examine the outcomes in patients with high-risk Stage I endometrial cancers surgically staged by complete pelvic and para-aortic lymphadenectomy, with negative nodes, and treated with postoperative brachytherapy. ⋯ Women undergoing hysterectomy for endometrial adenocarcinoma with high-risk node-negative disease confined to the uterus can be safely treated with brachytherapy, at a substantial cost savings, without compromising survival.
-
Gynecologic oncology · Sep 2001
Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
The aims of this study were to characterize hypersensitivity reactions to chemotherapy in patients with gynecologic malignancies and to determine the utility of oral and intravenous desensitization. ⋯ Hypersensitivity reactions to chemotherapeutic agents do not necessarily require exclusion of a compound from the treatment regimen. Intravenous and oral desensitization protocols are useful for successful and safe administration of paclitaxel and platinum compounds in patients with prior hypersensitivity reactions.
-
Gynecologic oncology · Aug 2001
Clinical TrialEffect of hemodilution on tissue perfusion and blood coagulation during radical hysterectomy.
The goal of this study was to evaluate the safety of hemodilution on global and splanchnic perfusion and blood coagulation during radical hysterectomy. ⋯ Hemodilution during radical hysterectomy, in this select group of patients, does not appear to compromise tissue perfusion or coagulation.